Exelixis, Inc. (EXEL)
$
38.67
-0.27 (-0.70%)
Key metrics
Financial statements
Free cash flow per share
2.7473
Market cap
10.6 Billion
Price to sales ratio
4.7599
Debt to equity
0.0884
Current ratio
3.5130
Income quality
1.2818
Average inventory
24.2 Million
ROE
0.2774
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Exelixis, Inc., a leading oncology-focused biotechnology firm, engages in the discovery, development, and commercialization of innovative therapeutic agents to treat various cancers in the United States. The weighted average number of diluted shares outstanding is 296,132,000.00 reflecting potential dilution effects from the company's equity structure. Among its portfolio, Exelixis markets CABOMETYX tablets, targeting advanced renal cell carcinoma patients who have undergone prior anti-angiogenic therapy, alongside COMETRIQ capsules designed for individuals with progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are based on cabozantinib, an inhibitor that affects multiple tyrosine kinases such as MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, a MEK inhibitor used in combination therapies for advanced melanoma, and MINNEBRO, an oral mineralocorticoid receptor blocker for hypertension in Japan. The diluted EPS is $1.76 accounting for potential share dilution. Furthermore, Exelixis has reported an interest expense of $0.00 indicating its obligations related to debt servicing. The cost of revenue for the company is $76,216,000.00 showcasing its production and operational expenses, while the gross profit stands at $2,092,485,000.00 highlighting profitability from core operations. In addition, the company continues to develop promising candidates such as XL092, XB002, and XL102, targeting various oncological indications. Exelixis, Inc. actively engages in research collaborations and licensing agreements with numerous esteemed organizations, further strengthening its position in the oncology landscape. The company, which was originally known as Exelixis Pharmaceuticals, Inc. before rebranding in February 2000, has its roots dating back to its incorporation in 1994 in Alameda, California. The stock is affordable at $40.10 making it suitable for budget-conscious investors interested in a promising oncology-focused company. Furthermore, the stock has a high average trading volume of 2,634,326.00 indicating strong liquidity in the market. With a mid-range market capitalization of $10,410,061,487.00 Exelixis is a steady performer in its sector. It is a key player in the Biotechnology industry, significantly contributing to the overall market landscape through its innovative therapeutic solutions. Additionally, the company belongs to the Healthcare sector, consistently driving innovation and growth as it develops new treatments for cancer patients.
Is Exelixis, Inc. (EXEL) a good investment?
Investing in Exelixis, Inc. (EXEL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Exelixis, Inc. (EXEL)'s stock forecast?
Analysts predict Exelixis, Inc. stock to fluctuate between $31.90 (low) and $49.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Exelixis, Inc.'s market capitalization?
As of 2025-10-31, Exelixis, Inc.'s market cap is $10,410,061,487, based on 269,202,521 outstanding shares.
How does Exelixis, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Exelixis, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Exelixis, Inc. (EXEL) stock?
To buy Exelixis, Inc. (EXEL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EXEL. Place an order (Market, Limit, etc.).
What is the best time to invest in Exelixis, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Exelixis, Inc. perform in the last earnings report?
Revenue: $2,168,701,000 | EPS: $1.80 | Growth: 0%.
Where can I find Exelixis, Inc.'s investor relations reports?
Visit https://www.exelixis.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Exelixis, Inc.?
You can explore historical data from here
What is the all-time high and low for Exelixis, Inc. stock?
All-time high: $49.62 (2025-06-23) | All-time low: $14.87 (2022-10-11).
What are the key trends affecting Exelixis, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Ethic Inc. trimmed its position in Exelixis, Inc. (NASDAQ: EXEL) by 12.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,309 shares of the biotechnology company's stock after selling 1,285 shares during the quarter. Ethic Inc.'s holdings in Exelixis were worth
zacks.com
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
businesswire.com
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met one of its dual primary endpoints, demonstrating a 20% reduction in the risk of death with the combination in.
businesswire.com
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical Oncology Congress (ESMO) during the Monday Poster Session: Neuroendocrine Tumours on October 20, 2025, from 12:00 – 12.
fool.com
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to be extremely risky clinical-stage biotechs that may no longer exist in five years.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
seekingalpha.com
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
prnewswire.com
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
See all news
